Phase II Study of ZD6474 in Advanced NSCLC
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00290537
- Locations
- 🇺🇸
University of Texas M.D.Anderson Cancer Center, Houston, Texas, United States
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00290511
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT00290498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00283621
- Locations
- 🇺🇸
UT MDAnderson Cancer Center, Houston, Texas, United States
Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00283582
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00276523
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00271505
- Locations
- 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-29
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00270907
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00267059
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00267085
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath